Clinical

Videos

"I think [at] the 2021 ASCO annual meeting, we saw a lot of novel data focusing on bladder-preservation approaches," says Shilpa Gupta, MD.

Dr. Gupta discusses bladder cancer research highlights from ASCO 2021

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

Articles

Investigators report that high urinary cotinine levels are associated with a greater risk of recurrence in smokers.

Nicotine metabolite linked to NMIBC recurrence

The approval is based on findings from the EV-301 and EV-201 trials.

FDA grants enfortumab vedotin regular approval for bladder cancer

Dr. Michael Devitt, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.

Dr. Devitt on circulating tumor cells in bladder cancer

Recent trial demonstrates an improvement in outcomes with an adjuvant immune checkpoint inhibitor in urothelial cancer.

Adjuvant immune checkpoint blockade in urothelial cancer: A new era?

Trilaciclib is a CDK4/6 inhibitor that has been shown to help lower the occurrence of chemotherapy-induced myelosuppression.

Trial launches of trilaciclib plus avelumab and chemo in bladder cancer

The PD-1 inhibitor met the primary end point in a monotherapy trial but fell short when used in a combination regimen in a separate trial. 

Split decision with published pembrolizumab data in bladder cancer

 is professor of surgery in the division of urology at Albany Medical College in New York.

"This study provides important and clinically useful information that can be used to plan the intensity of treatment and counsel our patients regarding the cancer-related and QOL-related outcomes after treatment," writes Badar M. Mian, MD.

QOL after bladder cancer treatment vs other cancers

In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.

AEs from Immunotherapy monotherapy for BCG-Unresponsive NMIBC

The Uro-G single-use device arrives at a time when the FDA is actively investigating reports of infections associated with reusable cystoscopes.

Bladder Cancer